Polycystic Kidney Disease Therapeutics Pipeline Analysis

Polycystic Kidney Disease Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS10979
Available Format:

The platform of new drugs for the polycystic kidney disease is increasing on account of less number of drugs available for treatment of the disease. Polycystic kidney disease is a form of rare disease and the drugs which are available for treatment, have an adverse effect on the health of patients. Currently, the prevalence of polycystic kidney disease in the U.S. ranges from 1 in 400 to 1 in 1000 which resulted in end stage renal disease by the age of 53. Around 600,000 patients are suffering from renal disease, out of which 2,000 patients start a renal replacement therapy every year. Increasing awareness in health-related issues is another factor responsible for the growth of polycystic kidney disease therapeutics pipeline.

Polycystic kidney disease is a disease which affects kidney along with other organs, in which development of cyst interrupts the ability to filter the waste products from blood. Enlargement of cyst may lead to kidney failure which can in turn impact other organs. Polycystic kidney disease is mostly related to high blood pressure, blood in urine, pain in back, kidney stones and heart valve abnormalities. People with polycystic kidney disease are at a risk of developing aneurysm in aorta or in blood vessels in base of the brain. Polycystic kidney disease is of two types as, autosomal dominant polycystic kidney disease, which begins in adulthood and autosomal recessive polycystic kidney disease. Autosomal dominant polycystic kidney disease can also be categorised as type 1 and type 2 subjected to genetic cause. The autosomal recessive polycystic kidney disease is a very rare and lethal form of disease, and its symptoms start appearing during birth or infancy. Polycystic kidney disease occurs mainly due to mutations in PKD1, PKD2 and PKHD1 genes.

Otsuka Pharmaceutical Development & Commercialization, Inc. is in the process of introducing a drug by the name, tolvaptan, which is currently in Phase III stage of development. The purpose of this study is to evaluate long term safety and efficacy in treatment of autosomal dominant polycystic kidney disease in children and adolescent. Tolvaptan, a vasopressin antagonist has greater affinity for V2 receptor than endogenous vasopressin.

Plexxikon, Inc. entered into an agreement with F. Hoffman-La Roche AG to develop and commercialize a second novel kinase inhibitor, PLX5568. It was agreed that F. Hoffman-La Roche AG would have a worldwide, exclusive license to develop and commercialize PLX5568, in addition to certain other selective Raf inhibitors resulting from the partnership. It was also agreed that, F. Hoffman-La Roche AG would pay Plexxikon, Inc. $60 million as an upfront payment. Plexxikon, Inc. also received approximately $275 million in payments over the term of the partnership based on the successful completion of a series of milestones for PKD. In addition, Plexxikon, Inc. was eligible to receive further payments based on the successful achievement of milestones for other compounds and indications. Separately, Plexxikon, Inc. received royalties for any sales that was related to products under the collaboration.

Some of the companies having a pipeline of polycystic kidney disease therapeutics include Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals Inc, Kyowa Hakko Kirin Co., Ltd., Catalyst Biosciences, Inc., Amgen, Inc., Angion Biomedica Corporation, Amyndas Pharmaceuticals LLC, Apellis Pharmaceuticals, Inc, Biogen, Inc, Astellas Pharma, Inc., Corline Biomedical AB, CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry